Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $6.00 Average Target Price from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.00.

Several research firms have issued reports on INO. Royal Bank of Canada dropped their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 2nd. StockNews.com upgraded Inovio Pharmaceuticals to a “sell” rating in a report on Monday, May 23rd. Oppenheimer downgraded Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 11th. Finally, Cantor Fitzgerald lowered their price target on Inovio Pharmaceuticals from $6.00 to $3.00 in a report on Wednesday, May 11th.

INO stock opened at $2.01 on Tuesday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 0.05. Inovio Pharmaceuticals has a 52-week low of $1.38 and a 52-week high of $9.96. The stock’s 50 day moving average is $2.17 and its two-hundred day moving average is $3.48. The company has a market capitalization of $460.37 million, a PE ratio of -1.31 and a beta of 0.82.

Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). Inovio Pharmaceuticals had a negative return on equity of 76.48% and a negative net margin of 20,479.29%. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.66 million. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. Inovio Pharmaceuticals’s revenue for the quarter was down 46.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Inovio Pharmaceuticals will post -1.19 EPS for the current year.

Hedge funds have recently made changes to their positions in the business. Qube Research & Technologies Ltd acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $434,000. RFG Advisory LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $52,000. Fox Run Management L.L.C. boosted its position in Inovio Pharmaceuticals by 69.2% during the 4th quarter. Fox Run Management L.L.C. now owns 18,786 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 7,683 shares during the period. Rafferty Asset Management LLC boosted its position in Inovio Pharmaceuticals by 64.6% during the 4th quarter. Rafferty Asset Management LLC now owns 1,232,071 shares of the biopharmaceutical company’s stock worth $6,148,000 after acquiring an additional 483,416 shares during the period. Finally, Tudor Investment Corp Et Al lifted its holdings in shares of Inovio Pharmaceuticals by 174.6% in the third quarter. Tudor Investment Corp Et Al now owns 273,854 shares of the biopharmaceutical company’s stock valued at $1,961,000 after buying an additional 174,133 shares during the period. Institutional investors own 43.28% of the company’s stock.

About Inovio Pharmaceuticals (Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Read More